Literature DB >> 8599961

The stereoisomers of 17alpha-[123I]iodovinyloestradiol and its 11beta-methoxy derivative evaluated for their oestrogen receptor binding in human MCF-7 cells and rat uterus, and their distribution in immature rats.

L J Rijks1, G J Boer, E Endert, K de Bruin, J C van den Bos, P A van Doremalen, W G Schoonen, A G Janssen, E A van Royen.   

Abstract

We studied the potential of both stereoisomers of 17alpha-[123I]iodovinyloestradiol (E- and Z-[123I]IVE) and of 11beta-methoxy-17alpha-[123I]iodovinyloestradiol (E- and Z-[123I]MIVE) as suitable radioligands for the imaging of oestrogen receptor(ER)-positive human breast tumours. The 17alpha-[123I]iodovinyloestradiols were prepared stereospecifically by oxidative radio-iododestannylation of the corresponding 17alpha-tri-n-butylstannylvinyloestradiol precursors. Competitive binding studies were performed in order to determine the relative binding affinity (RBA) of the unlabelled 17alpha-iodovinyloestradiols for the ER in both human MCF-7 breast tumour cells and rat uterine tissue, compared with that of diethylstilboestrol (DES). Target tissue uptake, retention and uptake selectivity of their 123I-labelled analogues were studied in immature female rats. All four 17alpha-iodovinyloestradiols showed high affinity for the ER in human MCF-7 cells, as well as rat uterus. Their RBA for the ER showed the following order of decreasing potency: RBA of DES >Z-IVE >Z-MIVE >E-MIVE > or =E-IVE. Neither of these 17alpha-iodovinyloestradiols showed any significant binding to the sex hormone binding globulin in human plasma. The biodistribution studies showed ER-mediated uptake in the uterus, ovaries and pituitary, that of E- and Z-[123I]MIVE being higher than that of E- and Z-[123I]IVE. High target-to-non-target tissue uptake ratios, especially at longer periods after injection (up to 24h), were exhibited by both isomers of [123I]MIVE. The uterus-to-blood uptake ratio was higher for E-[123I]MIVE. However, the uterus-to-fat uptake ratio appeared to be higher for the Z-isomer of [123I]MIVE, especially at 24h after injection. Metabolic properties and temperature effects, which play a more important role in vivo, probably cause the discrepancies seen between in vitro and in vivo binding results. On the basis of their in vitro binding properties and in vivo distribution characteristics we conclude that E- and Z-[123I]MIVE could be suitable radioligands for the diagnostic imaging of ER in human breast cancer. Therefore, further studies with these radioligands in mature normal and tumour-bearing rats are warranted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599961     DOI: 10.1007/bf00837628

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  59 in total

Review 1.  Epidemiology of breast cancer; a review.

Authors:  F de Waard
Journal:  Eur J Cancer Clin Oncol       Date:  1983-12

2.  Analysis and properties of the cytosolic estrogen receptor from rat thymus.

Authors:  D D Morgan; C J Grossman
Journal:  Endocr Res       Date:  1984       Impact factor: 1.720

3.  (2R*,3S*)-1-[125I]Iodo-2,3-bis(4-hydroxyphenyl)pentane ([125I]iodonorhexestrol) and (2R*,3S*)-1-[77Br]Bromo-2,3-bis(4-hydroxyphenyl)pentane ([77Br]bromonorhexestrol), two gamma-emitting estrogens that show receptor-mediated uptake by target tissues in vivo.

Authors:  S W Landvatter; J A Katzenellenbogen; K D McElvany; M J Welch
Journal:  J Med Chem       Date:  1982-11       Impact factor: 7.446

4.  Synthesis of A-ring fluorinated derivatives of (17 alpha,20E/Z)-[125I]iodovinylestradiols: effect on receptor binding and receptor-mediated target tissue uptake.

Authors:  H Ali; J Rousseau; J E van Lier
Journal:  J Med Chem       Date:  1993-10-15       Impact factor: 7.446

5.  16 beta-[18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors.

Authors:  H F VanBrocklin; P A Rocque; H V Lee; K E Carlson; J A Katzenellenbogen; M J Welch
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

6.  Factors affecting the target site uptake selectivity of estrogen radiopharmaceuticals: serum binding and endogenous estrogens.

Authors:  K D McElvany; K E Carlson; J A Katzenellenbogen; M J Welch
Journal:  J Steroid Biochem       Date:  1983-06       Impact factor: 4.292

7.  Structure-activity relationships of estrogenic ligands: synthesis and evaluation of (17 alpha, 20E)- and (17 alpha, 20Z)-21-halo-19-norpregna-1,3,5(10),20-tetraene-3,17 beta-diols.

Authors:  E Napolitano; R Fiaschi; R N Hanson
Journal:  J Med Chem       Date:  1991-09       Impact factor: 7.446

8.  Variation in receptor status between primary and metastatic breast cancer.

Authors:  I M Holdaway; J V Bowditch
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

9.  E-17 alpha[125I]iodovinylestradiol: an estrogen-receptor-seeking radiopharmaceutical.

Authors:  R N Hanson; D E Seitz; J C Botarro
Journal:  J Nucl Med       Date:  1982-05       Impact factor: 10.057

10.  Iodine-125--labeled estradiol: a gamma-emitting analog of estradiol that binds to the estrogen receptor.

Authors:  R B Hochberg
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.